Compare EVO & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | LMB |
|---|---|---|
| Founded | 1993 | 1901 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 914.9M |
| IPO Year | 2021 | 2014 |
| Metric | EVO | LMB |
|---|---|---|
| Price | $3.67 | $85.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $130.00 |
| AVG Volume (30 Days) | 68.7K | ★ 163.2K |
| Earning Date | 11-05-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.03 |
| EPS | N/A | ★ 3.03 |
| Revenue | ★ $887,396,457.00 | $603,582,000.00 |
| Revenue This Year | N/A | $28.00 |
| Revenue Next Year | $8.52 | $13.48 |
| P/E Ratio | ★ N/A | $27.59 |
| Revenue Growth | N/A | ★ 16.56 |
| 52 Week Low | $2.84 | $63.02 |
| 52 Week High | $4.80 | $154.05 |
| Indicator | EVO | LMB |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 56.72 |
| Support Level | $3.53 | $79.99 |
| Resistance Level | $3.81 | $87.72 |
| Average True Range (ATR) | 0.08 | 4.54 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 54.17 | 80.47 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.